Hexagon Nutrition IPO is one of the most talked-about public issues in the Indian primary market right now. Opening on June 5, 2026 and closing on June 9, 2026, the IPO is a ₹138.87 crore Offer for Sale (OFS) and will be listed on both the BSE and NSE, giving it significantly wider investor participation compared to a typical SME listing.
Before applying, investors should understand every key detail of the issue including the latest GMP (Grey Market Premium), price band, lot size, company financials, business strengths, risks, and overall investment outlook.
In this complete guide, we break down everything you need to know about the Hexagon Nutrition IPO, helping you decide whether this IPO deserves a place in your portfolio or is one you should avoid.
Table of Contents
Hexagon Nutrition IPO Overview
Incorporated in 1993, Hexagon Nutrition Limited is a research-driven nutrition company headquartered in Andheri (W), Mumbai. For over three decades, the company has developed and manufactured products across micronutrient premixes, branded wellness and clinical nutrition, therapeutic formulations, and ready-to-use foods serving both domestic consumers and international markets across 75+ countries.
The Hexagon Nutrition IPO is a 100% Offer for Sale (OFS) meaning no fresh capital enters the company. All proceeds go to the selling promoters. This is a key structural point investors must understand: the company receives zero funds from this IPO, which means no new capex, no debt reduction, and no working capital benefit from the issue.
Promoter holding drops significantly post-IPO, from 89.41% to 64.29% a reduction of 25.12 percentage points as the Kelkar family partially monetises their stake.
| Parameter | Detail |
|---|---|
| IPO Type | Bookbuilding — Mainboard |
| Total Issue Size | 3,08,59,704 shares (₹138.87 Cr) |
| Issue Structure | 100% Offer for Sale (OFS) |
| Listing Exchange | BSE + NSE (Mainboard) |
| Face Value | ₹1 per share |
| Pre-IPO Market Cap | ₹553.13 Crore |
| Promoter Holding (Pre-IPO) | 89.41% |
| Promoter Holding (Post-IPO) | 64.29% |
| Registrar | Kfin Technologies Ltd. |
| Lead Managers | Cumulative Capital Pvt. Ltd. + Catalyst Capital Partners Pvt. Ltd. |
Key Structural Note: A 100% OFS means all ₹138.87 crore goes to the selling shareholders, not the company. Before applying, evaluate whether the company’s existing financial position and growth trajectory justify the valuation without the benefit of IPO proceeds fuelling expansion.
Hexagon Nutrition IPO Dates & Complete Timeline
The Hexagon Nutrition IPO open date is June 5, 2026 (Friday) and closes on June 9, 2026 (Tuesday). Allotment happens on June 10, with the tentative listing date on June 12, 2026 on both BSE and NSE.
| Event | Date |
|---|---|
| IPO Open Date | Fri, Jun 5, 2026 |
| IPO Close Date | Tue, Jun 9, 2026 |
| Basis of Allotment | Wed, Jun 10, 2026 |
| Refunds Initiated | Thu, Jun 11, 2026 |
| Shares Credited to Demat | Thu, Jun 11, 2026 |
| Listing Date (Tentative) | Fri, Jun 12, 2026 |
| Bidding Cut-off Time | Jun 9, 2026 — 5:00 PM |
The IPO spans 5 calendar days including the weekend, giving investors a slightly extended window compared to the standard 3-day subscription period. The listing on Friday, June 12 means investors know their allotment outcome and can see the listing pop or gap down before the weekend.
Hexagon Nutrition IPO Price Band, Lot Size & Minimum Investment
The Hexagon Nutrition IPO price band is ₹42 to ₹45 per share, with a face value of ₹1. This is a low absolute price point making the lot size affordable in rupee terms and widening retail accessibility compared to higher-priced mainboard issues.
Lot Size & Investment Amounts
| Investor Category | Min Lots | Min Shares | Min Amount (Upper Band) |
|---|---|---|---|
| Retail (Min) | 1 | 333 | ₹14,985 |
| Retail (Max) | 13 | 4,329 | ₹1,94,805 |
| S-HNI (Min) | 14 | 4,662 | ₹2,09,790 |
| S-HNI (Max) | 66 | 21,978 | ₹9,89,010 |
| B-HNI (Min) | 67 | 22,311 | ₹10,03,995 |
Retail Investor Advantage: At just ₹14,985 for one lot (333 shares), this is one of the most accessible mainboard IPOs of 2026 by minimum investment. Retail investors can apply for up to 13 lots (₹1,94,805) well within the ₹2 lakh retail cap.
Issue Reservation Breakdown
| Category | Allocation |
|---|---|
| QIB (incl. Anchor) | Not more than 50% of Net Offer |
| NII / HNI | Not less than 15% of Net Offer |
| Retail (RII) | Not less than 35% of Net Offer |
The standard mainboard allocation gives retail investors a 35% floor a meaningfully better allotment probability than many oversubscribed SME issues where retail allocation is thinner.
Hexagon Nutrition IPO GMP Today
The Hexagon Nutrition IPO GMP (Grey Market Premium) has not yet started as of May 30, 2026, with grey market activity yet to establish a premium ahead of the June 5 opening. GMP typically begins forming 3–5 days before the IPO opens and strengthens or weakens as subscription data becomes visible.
What Is GMP and Why Does It Matter?
Grey Market Premium is the unofficial price at which IPO shares trade before listing outside regulated exchanges, entirely off-market. It reflects collective market sentiment about likely listing performance.
| GMP Signal | What It Means |
|---|---|
| GMP > ₹5 (positive) | Market expects listing above issue price |
| GMP = ₹0 | Neutral — listing at issue price expected |
| GMP negative | Market caution — listing loss risk |
GMP Disclaimer: Grey Market Premium is unregulated, unofficial, and can swing dramatically based on subscription levels, broader market movement, and sector sentiment. Never apply to any IPO solely based on GMP. The Hexagon Nutrition IPO fundamentals reviewed in the sections below should be the primary basis for your decision.
For live Hexagon Nutrition IPO GMP today, track it on platforms like InvestorGain, Chittorgarh.com, or IPO Watch all of which update GMP intraday once it becomes active.
Comparable Recent Pharma & Nutrition IPO Listings
| Company | Issue Size | Issue Price | Listing Day Close | Listing Gain |
|---|---|---|---|---|
| Corona Remedies Ltd. | ₹655.37 Cr | ₹1,062 | ₹1,438.40 | +35.44% |
| Rubicon Research Ltd. | ₹1,377.68 Cr | ₹485 | ₹628.20 | +29.53% |
| Sai Parenterals Ltd. | ₹408.79 Cr | ₹392 | ₹405.70 | +3.49% |
Recent pharmaceutical and nutrition-adjacent IPO listings have ranged from modest (+3.49%) to exceptional (+35.44%). Hexagon Nutrition’s unique positioning in clinical nutrition and therapeutic foods differentiates it from pure pharma plays, but investor sentiment toward the broader healthcare sector remains a key driver.
Hexagon Nutrition Financials & Key Performance Indicators
Hexagon Nutrition’s financial trajectory shows consistent improvement across all key metrics, with PAT more than doubling over two fiscal years from ₹5.82 Cr in FY2023 to ₹24.38 Cr in FY2025, and already at ₹27.03 Cr for the nine months ending December 2025.
Financial Summary (₹ Crore — Consolidated, Restated)
| Metric | 9M FY2026 (Dec 2025) | FY2025 | FY2024 | FY2023 |
|---|---|---|---|---|
| Total Income | 275.57 | 331.29 | 304.62 | 281.65 |
| Profit After Tax (PAT) | 27.03 | 24.38 | 12.21 | 5.82 |
| EBITDA | 37.55 | 40.07 | 24.88 | 17.17 |
| Net Worth | 223.05 | 195.60 | 176.29 | 163.84 |
| Total Borrowings | 39.79 | 26.60 | 36.89 | 51.87 |
| Total Assets | 327.60 | 261.36 | 250.54 | 288.90 |
A few numbers stand out immediately:
- PAT grew 319% in two years — from ₹5.82 Cr (FY23) to ₹24.38 Cr (FY25)
- EBITDA margin expanded from 6.1% (FY23) to 12.33% (FY25) to 14.03% (9M FY26) — a sustained margin improvement story
- Total borrowings reduced from ₹51.87 Cr (FY23) to ₹26.60 Cr (FY25), with a slight uptick to ₹39.79 Cr in 9M FY26
- The nine-month PAT of ₹27.03 Cr already exceeds the full-year FY25 PAT of ₹24.38 Cr — strong FY26 earnings trajectory
Key Performance Indicators
| KPI | Dec 31, 2025 (9M) | Mar 31, 2025 |
|---|---|---|
| Return on Equity (ROE) | 13.02% | 10.47% |
| Return on Capital Employed (ROCE) | 14.82% | 17.06% |
| EBITDA Margin | 14.03% | 12.33% |
| PAT Margin | 9.81% | 7.36% |
| Debt-to-Equity | 0.18x | 0.14x |
| Price-to-Book Value | 2.48x | 2.83x |
| EPS (Pre-IPO) | ₹1.98 | — |
| EPS (Post-IPO) | ₹2.93 | — |
| P/E (Post-IPO, Upper Band) | 15.35x | 22.69x |
Valuation Note: The post-IPO P/E of 15.35x (based on annualised 9M earnings) appears reasonable for a branded nutrition company with improving margins and an international export footprint. The EPS improves post-IPO from ₹1.98 to ₹2.93 because the OFS structure does not dilute the share count — the higher EPS post-IPO reflects annualisation of the 9-month earnings, which are tracking ahead of FY25.
Manufacturing Capacity & Distribution Reach
- 3 manufacturing facilities in India — Nasik (Maharashtra), Chennai (Tamil Nadu), Thoothukudi (Tamil Nadu)
- 1 international facility — Tashkent, Uzbekistan
- Chennai and Thoothukudi plants are in SEZ zones — duty-free imports, port proximity
- 2 dedicated R&D facilities — Nasik and Chennai, staffed by 12 qualified professionals
- 358+ distributors across India, including 8 with multi-state presence
- Exports to 75+ countries across Asia, Africa, Europe, and South America
- 527 employees as of March 31, 2026
Hexagon Nutrition Strengths & Risk Factors
Key Strengths
1. Three Distinct Revenue Segments — Diversification by Design Hexagon Nutrition operates across B2C (branded wellness and clinical nutrition), B2B2C (micronutrient premix formulations), and ESG-linked products (ready-to-use therapeutic foods and micronutrient powders). This three-segment structure means no single revenue stream dominates and the ESG segment plugs the company directly into global humanitarian nutrition programmes.
2. Genuine Export Footprint Across 75+ Countries The company has exported products to over 75 countries between FY23 and FY25 a rare achievement for an Indian nutrition company at this scale. International offices in South Africa, Uzbekistan, and Hong Kong signal a deliberate global expansion strategy, not opportunistic one-time exports.
3. SEZ Manufacturing Advantage Two of its three Indian manufacturing facilities are in SEZ zones structurally advantaged for export-oriented production through duty-free imports and port proximity. This directly supports margin improvement in the international business.
4. PAT Growing at 319% Over Two Years A near-5x increase in profit after tax from FY23 to FY25, with the first nine months of FY26 already exceeding the full FY25 PAT this is genuine financial acceleration, not a one-year anomaly.
5. Low Debt-to-Equity (0.18x) At 0.18x Debt/Equity as of December 2025, Hexagon Nutrition maintains a conservative balance sheet. Total borrowings of ₹39.79 Cr against a net worth of ₹223.05 Cr give it significant headroom for growth capex without financial stress.
6. Research-Driven Moat The company operates two dedicated in-house R&D facilities. In clinical nutrition and therapeutic foods regulated, prescription-adjacent categories R&D capability creates a product development moat that generic commodity manufacturers cannot easily replicate.
7. Omnichannel Distribution Network Hexagon Nutrition sells through retail pharmacies, hospitals, e-commerce platforms (including its own branded sites Pentasure, Obesigo, Pediagold, and Nutrone), and online pharmacies. This multi-channel presence reduces dependence on any single distribution format.
Key Risks
1. 100% OFS — Zero Proceeds to the Company This is the single most important structural risk. Since the IPO is entirely an offer for sale, the company receives no capital for growth. If future capex requirements arise, the company must self-fund or borrow without the benefit of IPO proceeds.
2. Significant Promoter Stake Reduction Promoter holding drops from 89.41% to 64.29% a 25-percentage-point reduction. While 64.29% still signals majority control, the scale of the monetisation warrants scrutiny of promoter intent and long-term commitment to the business.
3. Modest Scale for a Mainboard Listing With total income of ₹331 Cr in FY25 and a pre-IPO market cap of ₹553 Cr, Hexagon Nutrition is at the smaller end of the mainboard spectrum. Revenue scaling and market share gains will be closely watched post-listing.
4. Working Capital Dynamics Total borrowings increased from ₹26.60 Cr (FY25) to ₹39.79 Cr (9M FY26) a near-50% jump in nine months, suggesting working capital requirements are rising as the business scales. Monitor this closely in post-listing quarterly results.
5. Competitive Nutrition Market India’s clinical and wellness nutrition market is intensely competitive, with established players like Abbott (Ensure, Pediasure), Danone (Protinex, Aptamil), Nestlé (NAN, Milo), and multiple domestic FMCG companies. Hexagon Nutrition competes on price, distribution, and clinical differentiation.
6. Dependence on B2B2C Premix Business If the micronutrient premix B2B2C segment — which supplies to food manufacturers, government programmes, and institutional buyers — faces pricing pressure or contract losses, it could meaningfully impact consolidated revenue.
Hexagon Nutrition IPO Review — Should You Apply?
What the Expert Says
Dilip Davda, one of India’s most respected independent IPO analysts, has assessed the Hexagon Nutrition IPO as follows:
“HNL is a pure play nutrition company having differentiated and research-oriented products play. It posted steady growth in its top and bottom lines for the reported periods. It is a most preferred partner/supplier for nutritional products with a rising market share. Based on its recent financial data, the issue appears fully priced. Well-informed investors may park funds for medium to long term.”
The broker community has not yet issued formal recommendations as of this writing — watch for updated calls as the subscription period opens.
Our Analysis: Three Scenarios
Scenario A — Bull Case (Apply for Medium-Long Term) The post-IPO P/E of 15.35x is genuinely reasonable for a branded nutrition company with PAT growing at this pace, an international presence in 75+ countries, and expanding EBITDA margins. If FY26 full-year PAT annualises to ₹35–38 Cr, the P/E re-rates even lower, making the current entry attractive for a 2–3 year hold.
Scenario B — Base Case (Apply with Modest Listing Gain Expectations) Given the accessible ₹14,985 minimum investment and mainboard listing on both BSE and NSE, subscription levels are likely to be strong across retail and HNI categories. A modest listing gain of 10–20% is plausible if GMP develops positively in the week ahead.
Scenario C — Bear Case (Skip if Concerned about OFS Structure) The 100% OFS nature and significant promoter stake reduction are legitimate concerns for investors who prefer companies using IPO funds for growth rather than promoter monetisation. If broader markets correct before June 12 listing, the thin GMP buffer could erode quickly.
Verdict Table
| Investor Profile | Recommendation |
|---|---|
| Long-term growth investors (nutrition theme) | Apply |
| Investors comfortable with OFS structure | May Apply |
| Investors seeking listing-day gains | Wait for GMP confirmation |
| Conservative investors (prefer fresh issue) | Caution — OFS only |
Also Read
- Best Dividend Yield Stocks in India 2026: Top 20 High Dividend Paying Shares
- Adani Power Share Price Target 2026–2030 — 5 Shocking Facts Every Investor Must Know
- Defence Stocks in India 2026: Best Defence Shares to Watch, Buy & Track
- Merritronix IPO 2026: Complete Review, GMP, Price Band, Dates & Should You Apply?
Frequently Asked Questions(FAQ)
Q.1. What is the Hexagon Nutrition IPO price band?
Ans:- The Hexagon Nutrition IPO price band is ₹42 to ₹45 per share, with a face value of ₹1 per share.
Q.2. What is the Hexagon Nutrition IPO lot size and minimum investment?
Ans:- The lot size is 333 shares. Retail investors can apply for a minimum of 1 lot (333 shares) at ₹14,985 at the upper price band one of the most accessible minimum investment amounts in 2026 mainboard IPOs.
Q.3. What is the Hexagon Nutrition IPO allotment date?
Ans:- The allotment date is Wednesday, June 10, 2026. Refunds and demat credit happen on Thursday, June 11, 2026.
Q.4. What is Hexagon Nutrition IPO GMP today?
Ans:- As of May 30, 2026, the GMP has not yet started. Check live rates on InvestorGain, Chittorgarh.com, or IPOWatch.in GMP typically activates 3–5 days before the IPO opens on June 5.
Q.5. When does Hexagon Nutrition IPO list?
Ans:- The Hexagon Nutrition IPO listing date is June 12, 2026 (tentative Friday), on both BSE and NSE mainboard.
Q.6. What does Hexagon Nutrition do?
Ans:- Hexagon Nutrition is a research-driven nutrition company incorporated in 1993. It develops and manufactures micronutrient premixes (B2B2C), branded clinical and wellness nutrition (B2C), and therapeutic ready-to-use foods (RUFs/MNPs). Products are sold across India through 358+ distributors and exported to 75+ countries. Key consumer brands include Pentasure, Obesigo, Pediagold, and Nutrone.
Q.7. Is the Hexagon Nutrition IPO a fresh issue or OFS?
Ans:- The Hexagon Nutrition IPO is a 100% Offer for Sale (OFS). The company receives no proceeds — all ₹138.87 crore goes to the selling promoters (Arun Purushottam Kelkar, Subhash Purushottam Kelkar, Vikram Arun Kelkar, and Nikhil Arun Kelkar).
Q.8. Who is the registrar of the Hexagon Nutrition IPO?
Ans:- Kfin Technologies Ltd. is the registrar. Check allotment status at the Kfin Technologies IPO portal or on BSE (bseindia.com/investors/appli_check.aspx) after June 10, 2026.
Conclusion
The Hexagon Nutrition IPO brings a 33-year-old, R&D-led nutrition company to India’s mainboard exchanges at a moment when clinical nutrition, therapeutic foods, and micronutrient science are gaining global institutional attention. The company’s financials are improving, its export reach is genuinely rare at this scale, and its post-IPO valuation of 15.35x P/E is not demanding.
The structural caveat a 100% OFS with promoters reducing their holding by 25 percentage points is real and should be factored into every application decision.
For investors who can look beyond the OFS and focus on a 2–3 year nutrition sector theme, the Hexagon Nutrition IPO represents a reasonably priced entry into one of India’s most structurally growing consumer health categories.
Check the GMP in the days ahead. Subscribe if it turns positive and the fundamentals align with your portfolio thesis.
Disclaimer:- Always read the Red Herring Prospectus (RHP) before applying. This article is for informational and educational purposes only and does not constitute financial advice. IPO investments are subject to market risks. Consult a SEBI-registered investment advisor before making investment decisions